How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analyst estimates of $2.81 million.

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE) , Synergy Pharmaceuticals (SGYP) , Progenics Pharmaceuticals (PGNX) , Sangamo Therapeutics (SGMO) , Amarin (AMRN) , Anavex Life Sciences (AVXL) and Freeport-McMoRan (FCX) .

How do I buy shares of Asterias Biotherapeutics?

Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:AST

Asterias Biotherapeutics (AST) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free AST Stock Alerts

$0.0020

0.00 (0.00%)

(As of 07/10/2019)

Compare

Today's Range: $0.0020
▼
$0.0020
50-Day Range: N/A
52-Week Range: $0.51
▼
$2.05

Volume: 1,000 shs
Average Volume: 136,653 shs
Market Capitalization: $111,318.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Asterias Biotherapeutics alerts:

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Asterias Biotherapeutics Stock (NYSEAMERICAN:AST)

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

AST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AST Stock News Headlines

March 27, 2024 | seekingalpha.com

CLDI Calidi Biotherapeutics, Inc.

February 17, 2024 | morningstar.com

Protalix BioTherapeutics Inc PLX

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

November 27, 2023 | benzinga.com

Calidi Biotherapeutics Stock (AMEX:CLDI) Dividends: History, Yield and Dates

November 22, 2023 | morningstar.com

Barinthus Biotherapeutics PLC ADR

November 2, 2023 | morningstar.com

Calidi Biotherapeutics Inc Ordinary Shares - Class A

July 18, 2023 | benzinga.com

Arcutis Biotherapeutics Stock (NASDAQ:ARQT), Analyst Ratings, Price Targets, Predictions

May 21, 2023 | fool.com

Iovance Biotherapeutics (NASDAQ: IOVA)

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

May 11, 2023 | marketwatch.com

Human Embryonic Stem Cells (HESC) Market Future Investments and Forecast Till 2030

May 8, 2023 | investing.com

BrightPath Biotherapeutics Co Ltd (4594)

March 14, 2023 | marketwatch.com

Human Embryonic Stem Cells (HESC) Market: Analyzing Growth Opportunities and Industry Trends for 2023-2028

March 9, 2023 | marketwatch.com

2023-2029 Human Embryonic Stem Cells (HESC) Market Size and Regional Analysis | Research Report by Absolute Reports

March 7, 2023 | marketwatch.com

Stem Cell Therapy for Osteoarthritis Market Expert Industrial Investigation Report 2023-2028

March 6, 2023 | marketwatch.com

Therapeutic Cancer Vaccines Market 2023 | Global Industry Report Forecast 2029

February 27, 2023 | marketwatch.com

Emerging Opportunities in Therapeutic Cancer Vaccines Market from 2023 to 2027

February 20, 2023 | seekingalpha.com

Atara Biotherapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 14, 2023 | marketwatch.com

Therapeutic Cancer Vaccines Market Outlook 2023 and Forecast to 2028 with Top Countries Data

January 30, 2023 | finance.yahoo.com

Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023

January 20, 2023 | seekingalpha.com

SONN Sonnet BioTherapeutics Holdings, Inc.

January 19, 2023 | marketwatch.com

Human Embryonic Stem Cells (HESC) Market By Industry Research, Supply, Size, Share and Prospects 2023-2028

January 11, 2023 | marketwatch.com

Sonnet BioTherapeutics Shares Up 8% on Roche Collaboration

January 5, 2023 | finance.yahoo.com

Kling Biotherapeutics Appoints Michael Koslowski, M.D. As Chief Executive Officer

December 20, 2022 | finance.yahoo.com

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

November 27, 2022 | marketwatch.com

Human Embryonic Stem Cells (HESC) Market 2022 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028

November 27, 2022 | marketwatch.com

Human Embryonic Stem Cells (HESC) Market 2022 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028

November 25, 2022 | marketwatch.com

Therapeutic Cancer Vaccines Market 2023 : SWOT Analysis by Players Continues Explosive Growth by 2028

See More Headlines

Receive AST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2017
Today: 4/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:AST
Previous Symbol: NYSEMKT:AST
CUSIP: N/A
CIK: N/A
Web: asteriasbiotherapeutics.com
Phone: +1-510-4563805
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 55,659,000
Free Float: N/A
Market Cap: $111,318.00
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Michael H. Mulroy (Age 53)
CEO, Pres & Director
Dr. Edward D. Wirth III (Age 54)
Chief Medical Officer
Dr. Katharine E. Spink (Age 45)
Consultant
Mr. Stephen L. Cartt (Age 56)
Advisor & Director
Mr. Ryan D. Chavez (Age 43)
CFO & Gen. Counsel

Key Competitors

View All Competitors

AST Stock Analysis - Frequently Asked Questions

How were Asterias Biotherapeutics' earnings last quarter?: Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analyst estimates of $2.81 million.
What other stocks do shareholders of Asterias Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), Amarin (AMRN), Anavex Life Sciences (AVXL) and Freeport-McMoRan (FCX).
How do I buy shares of Asterias Biotherapeutics?: Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:AST) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial